Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference
By: GlobeNewswire - 19 Feb 2020Back to overview list

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today that Scott Clarke, Chief Executive Officer, will present at The Cowen and Company 40th Annual Healthcare Conference on Wednesday, March 4th at 2:00pm ET in Boston, MA.

The corporate presentation will be made available on the “news” section of the Tizona website at www.tizonatx.com.

About Tizona Therapeutics, Inc. 

Tizona is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people with cancer. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Tizona’s lead program, TTX-030, a first-in-class anti-CD39 antibody, is being developed in collaboration with AbbVie. It is currently being studied in a phase 1/1b clinical trial as a monotherapy and in combination with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556).

Contact:

Investors:
Shari Annes, Annes Associates
sannes@annesassociates.com
650-888-0902 

Media:
Janet Graesser
jgraesser@tizonatx.com
917-685-8799

Copyright 2020 GlobeNewswire Back to overview list
to the top ↑